Stockreport

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor

Revolution Medicines, Inc.  (RVMD) 
PDF KRASG12C(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring KRASG12C mutation RMC-6291 is first mutant-se [Read more]